health
nih
offic
biotechnolog
activ
oba
complianc
nih
guidelin
fda
assess
safeti
ultim
effect
adenoviruscontain
product
involv
thorough
evalu
inform
contain
ind
support
inform
crossreferenc
anoth
ind
drug
master
file
type
inform
contain
ind
set
forth
cfr
subpart
b
follow
section
describ
mani
agenc
requir
guidanc
regard
drug
develop
adenoviralcontain
product
puriti
safeti
potenc
adenovirusbas
vector
use
first
time
human
major
goal
fda
oversight
ensur
safeti
patient
receiv
investig
product
crucial
compon
safeti
effect
care
attent
detail
manufactur
product
character
extent
qualiti
inform
allow
assess
puriti
final
vector
prepar
administ
patient
assess
puriti
involv
biolog
biochem
character
vector
prepar
assess
hov
complet
formul
product
conform
expect
characterist
adenoviru
vector
assess
puriti
includ
structur
biochem
inform
vector
well
demonstr
freedom
unexpect
potenti
harm
agent
virus
fungi
bacteria
bacteri
toxin
anoth
import
goal
product
character
assess
potenc
adenoviru
vector
prepar
potenc
measur
intend
determin
extent
vhich
particular
vector
prepar
desir
biolog
activ
vector
prepar
vith
insuffici
potenc
littl
chanc
behav
desir
clinic
trial
although
infecti
titer
propos
measur
potenc
current
consid
suffici
sinc
correl
vitro
infecti
assay
biolog
effect
establish
potenc
relat
safeti
efficaci
also
indic
product
manufactur
consist
direct
measur
potenc
new
adenoviru
vector
product
often
challeng
due
lack
appropri
vitro
vivo
system
measur
potenc
therefor
initi
phase
product
develop
demonstr
transgen
activ
enzymat
mean
often
adequ
initi
clinic
trial
develop
bona
fide
potenc
assay
vector
lot
releas
requir
fda
licens
adenoviru
product
gener
expect
potenc
assay
place
phase
thu
biolog
therapeut
product
assess
puriti
safeti
potenc
adenoviru
vector
crucial
part
product
develop
complex
adenoviru
vector
manufactur
vell
inher
biolog
properti
product
system
varrant
oversight
product
process
well
final
product
inde
complex
biolog
product
order
assur
puriti
potenc
safeti
adenoviru
vector
regul
manufactur
process
import
character
test
final
product
therefor
thorough
character
start
materi
product
intermedi
order
assur
final
vector
product
accept
administr
human
initi
develop
new
adenoviru
vector
involv
manipul
clone
transgen
cassett
desir
gene
appropri
transcript
regulatori
element
commonli
use
approach
vector
product
appropri
cell
line
cotransfect
transgen
cassett
backbon
shuttl
vector
suppli
remain
compon
adenoviru
genom
appropri
cell
line
allow
homolog
recombin
transgen
backbon
plasmid
support
synthesi
replicationdefect
adenoviru
particl
abil
mediat
homolog
recombin
allow
assembl
desir
vector
abil
also
lead
unintend
structur
chang
thu
crucial
select
vector
clone
fulli
character
intend
structur
sinc
cell
line
also
use
propag
vector
product
viru
bank
largescal
product
import
monitor
structur
vector
sever
stage
manufactur
cell
line
use
product
adenoviru
vector
add
anoth
complex
biolog
compon
manufactur
process
character
cell
line
includ
master
cell
bank
work
cell
bank
describ
detail
section
vi
principl
current
good
manufactur
practic
cgmp
per
cfr
appli
adenoviru
gene
transfer
product
howev
implement
cgmp
may
stage
accord
phase
product
develop
alway
appropri
document
manufactur
qualiti
oversight
phase
includ
appropri
written
protocol
stage
product
manufactur
character
later
stage
product
develop
appropri
document
manufactur
employ
standard
oper
procedur
sop
captur
import
inform
relat
vector
product
qualiti
oversight
alway
involv
qualiti
control
qc
qualiti
assur
qa
mechan
regardless
manufactur
take
place
essenc
mean
person
respons
assur
product
character
test
perform
properli
met
specifi
criteria
qualiti
assur
separ
direct
subordin
person
respons
conduct
test
file
report
qualiti
control
product
develop
move
phase
later
phase
cgmp
also
stipul
develop
valid
assay
must
place
product
hcensur
data
regard
assay
perform
specif
sensit
reliabl
submit
agenc
part
valid
process
mani
factor
contribut
develop
fda
recommend
requir
character
adenoviru
vector
first
regul
found
variou
applic
part
code
feder
regul
cfr
includ
regulatori
requir
biolog
product
administ
human
must
steril
cfr
anoth
vahd
altern
test
equal
sensit
free
mycoplasma
cfr
meet
endotoxin
limit
limulu
amebocyt
lysat
lal
per
cfr
pyrogen
test
cfr
b
estabfish
minimum
criteria
assur
product
administ
human
contamin
microbi
organ
toxic
byproduct
next
fda
review
staff
accumul
experi
review
mani
adenoviru
vector
gene
therapi
product
reviev
maintain
activ
research
program
area
relat
adenoviru
biolog
particip
research
past
cber
review
regular
intern
meet
discuss
relev
issu
develop
consist
oversight
adenoviru
vector
product
major
effort
regard
va
launch
march
issuanc
letter
gene
therapi
sponsor
request
comprehens
inform
product
preclin
clinic
qaqc
area
see
section
xvi
data
tremend
use
use
refin
cber
recommend
regard
adenoviru
vector
product
cumul
experi
fda
review
also
util
develop
guidanc
document
sever
relev
manufactur
adenoviru
gene
transfer
product
experi
gene
therapi
commun
also
play
key
role
develop
fda
recommend
regul
adenoviru
vector
product
experi
adenoviru
vector
manufactur
commun
meet
manufactur
fda
staff
present
scientif
meet
present
nih
recombin
dna
advisori
committe
rac
nih
rac
play
import
role
develop
recommend
provid
public
forum
discuss
follov
death
patient
gene
therapi
trial
late
rac
empanel
ad
hoc
advisori
group
rac
work
group
adenovir
vector
safeti
toxic
adsat
examin
data
adenoviru
gene
transfer
trial
vith
intent
formul
recommend
improv
safeti
clinic
trial
one
import
discuss
center
accuraci
adenoviru
vector
titer
term
total
particl
infecti
particl
titer
sinc
toxic
vector
dose
dose
potenti
therapeut
effect
va
particular
concern
lack
accuraci
compar
titer
determin
differ
product
lot
differ
clinic
trial
discuss
highlight
need
refer
standard
could
use
help
standard
adenoviru
vector
titer
measur
public
discuss
help
stimul
gene
therapi
commun
initi
develop
standard
sever
public
meet
develop
consensu
need
standard
discuss
natur
refer
materi
discuss
mechan
develop
held
late
earli
adenoviru
refer
materi
work
group
armwg
form
auspic
williamsburg
bioprocess
foundat
wbf
wbpfda
partnership
agreement
formul
allow
particip
fda
staff
develop
refer
stock
wildtyp
adenoviru
type
use
calibr
assay
particl
number
infect
role
fda
lend
scientif
regulatori
expertis
form
recommend
armwg
overse
develop
refer
materi
inform
initi
avail
wbf
websit
wwwwilbiocom
cber
websit
wwwcberfdagov
inform
includ
meet
minut
transcript
fda
cosponsor
meet
explan
bid
mechan
particip
volunt
donat
good
servic
toward
product
character
refer
materi
refer
materi
provid
anoth
mechan
fda
formul
recommend
character
adenovirusbas
gene
transfer
product
fda
also
seek
input
advisori
committe
biolog
respons
modifi
advisori
committe
brmac
recommend
regard
character
adenoviru
vector
brmac
meet
allow
fda
obtain
advic
scientif
issu
impact
gene
transfer
experi
public
forum
interest
parti
allow
particip
transcript
meet
also
avail
cber
websit
wwwcberfdagov
brmac
advic
issu
amount
type
structur
character
gene
transfer
vector
discuss
two
recent
committe
meet
valuabl
cber
staff
develop
updat
polici
summari
fda
receiv
input
feedback
varieti
sourc
formul
recommend
regard
adenoviru
manufactur
character
recommend
may
chang
vith
advanc
technolog
accumul
experi
fda
consid
potenti
risk
benefit
vector
product
propos
clinic
trial
make
recommend
casebycas
approach
vhich
take
account
sever
diseas
propos
patient
popul
permit
flexibl
product
manufactur
character
goal
adenoviru
vector
manufactur
produc
safe
pure
efficaci
vector
complex
process
necessit
care
control
entir
manufactur
procedur
compon
use
raw
materi
sourc
adventiti
agent
toxic
impur
neg
impact
safeti
final
product
earli
stage
product
develop
certif
analysi
coa
mani
raw
materi
buffer
basic
tissu
cultur
compon
part
document
demonstr
reagent
pure
free
adventiti
agent
coa
kept
manufactur
record
sampl
coa
submit
agenc
later
stage
product
develop
develop
test
accept
criteria
materi
may
requir
sponsor
exampl
current
techniqu
adenoviru
vector
product
requir
mammalian
cell
substrat
raw
materi
includ
sourc
serum
usual
fetal
bovin
serum
fb
enzym
porcin
trypsin
cell
cultur
reagent
contamin
adventiti
viru
trypsin
identifi
potenti
sourc
porcin
parvoviru
fb
harbor
sever
adventiti
virus
therefor
fb
porcin
trypsin
come
sourc
appropri
test
conduct
document
coa
manufactur
adenoviru
vector
retain
coa
submit
sampl
copi
fda
also
bovin
serum
geograph
area
known
harbor
endem
bovin
spongiform
encephalopathi
agent
bse
consid
inappropri
use
manufactur
biolog
use
human
sinc
adenoviru
vector
product
reli
cell
support
replic
vector
cell
bank
import
aspect
product
cell
bank
cryopreserv
stockpil
consist
well
character
cell
popul
shown
free
adventiti
viru
steril
capac
support
product
adenoviru
vector
ideal
cell
bank
deriv
earli
cell
passag
assur
reliabl
consist
sourc
qualifi
cell
avail
forese
futur
product
need
detail
necessari
character
cell
bank
discuss
belov
similar
fashion
viru
bank
import
aspect
adenoviru
product
viru
bank
consist
frozen
stock
vell
character
molecular
vector
clone
character
includ
structur
physicalbiochem
function
assess
addit
assess
microbi
steril
freedom
adventiti
virus
viru
bank
deriv
earli
step
vector
manufactur
assur
reliabl
sourc
infecti
vector
avail
forese
futur
product
need
detail
necessari
character
viru
bank
discuss
protocol
use
step
manufactur
import
record
demonstr
product
process
start
materi
vector
product
qualiti
suffici
assur
final
product
pure
safe
detail
descript
step
maintain
submit
fda
part
ind
mani
protocol
integr
part
manufactur
part
standard
oper
procedur
see
even
though
mani
protocol
molecular
biolog
techniqu
use
assembl
vector
repeat
step
detail
protocol
stage
essenti
control
manufactur
process
obtain
test
character
intermedi
final
product
product
scheme
adenoviru
vector
includ
character
cell
substrat
master
work
cell
bank
viru
seed
stock
master
viru
bank
bulk
vector
prepar
final
formul
product
detail
test
outlin
goal
process
control
twofold
ensur
safe
pure
efficaci
vector
product
demonstr
product
process
highli
reproduc
standard
oper
procedur
mechan
ensur
process
control
protocol
product
manufactur
character
carri
reproduc
document
fashion
stage
manufactur
product
test
sop
consist
detail
written
document
describ
step
process
conduct
manufactur
sop
also
refer
mani
differ
type
process
impact
adenoviru
product
requir
train
personnel
acquisit
accept
raw
materi
procedur
ship
handl
final
product
conduct
qualiti
oversight
earli
product
develop
sop
develop
manufactur
test
step
discuss
belov
later
stage
product
develop
consult
fda
advis
assur
comprehens
coverag
manufactur
process
appropri
sop
qualiti
assur
qualiti
control
program
consid
essenti
step
assur
safe
highqual
adenoviru
vector
product
key
concept
qaqc
program
separ
author
personnel
respons
conduct
test
manufactur
personnel
examin
approv
test
data
final
product
character
accomplish
varieti
way
instanc
separ
qa
qc
depart
institut
use
provid
respons
personnel
direct
supervis
one
anoth
import
topic
often
misunderstood
divis
respons
ind
sponsor
multius
facil
contract
part
product
manufactur
facil
use
produc
one
gene
transfer
vector
term
multius
facil
mani
genetherapi
vector
produc
multius
facil
ind
sponsor
often
assum
contract
lab
provid
necessari
qaqc
manufactur
product
test
inform
fda
involv
suffici
design
test
examin
data
andor
answer
fda
question
although
contract
lab
play
import
role
respons
oversight
qaqc
report
lie
sponsor
sponsor
must
recogn
fda
hold
account
oversight
product
test
conduct
contract
organ
addit
concern
multius
facil
potenti
crosscontamin
one
product
product
made
previous
concurr
multius
facil
test
crosscontamin
valid
product
purif
process
rule
crosscontamin
entir
product
process
raw
materi
oversight
test
product
releas
import
assur
adenoviru
gene
transfer
vector
safe
consist
possibl
next
section
describ
greater
detail
character
done
major
compon
intermedi
well
final
product
adenoviru
vector
product
includ
cell
bank
viru
bank
bulk
viru
prepar
final
vector
product
necess
specif
character
assess
casebycas
basi
chang
depend
phase
product
develop
resuh
feedback
numer
sourc
discuss
therefor
follow
materi
intend
give
reader
overviev
fda
expect
consult
cber
preind
stage
strongli
recommend
test
cell
bank
use
adenoviru
vector
product
two
gener
type
safeti
test
character
tabl
overview
recommend
character
safeti
test
intend
demonstr
cell
bank
free
detect
microbi
contamin
includ
bacteri
fungal
viral
steril
test
univers
requir
biolog
set
forth
cfr
altern
steril
assay
valid
equal
sensit
may
also
use
basic
premis
appli
product
case
cell
master
cell
bank
sever
grovth
media
look
outgrowth
microbi
contamin
cours
day
specif
test
contamin
mycoplasma
test
conduct
inocul
cell
cell
supernat
appropri
cultur
examin
growth
necess
specif
character
assess
casebycas
basi
chang
depend
phase
product
develop
result
feedback
numer
sourc
discuss
therefor
list
intend
give
reader
overview
fda
oversight
hovev
consult
cber
strongli
recommend
submiss
ind
mycoplasma
test
describ
fda
guidelin
altern
test
pcr
could
util
follow
proper
demonstr
sensit
compar
culturebas
assay
adventiti
viru
test
also
intend
show
test
materi
free
varieti
virus
vitro
adventiti
viru
test
conduct
inocul
cell
cultur
test
materi
case
supernat
master
cell
bank
mcb
follow
day
cultur
cell
test
abil
mediat
hemadsorpt
hemagglutin
red
blood
cell
three
differ
speci
cell
line
chosen
abil
support
replic
detect
mani
differ
virus
list
virus
detect
given
tabl
ii
vitro
adventiti
viru
assay
provid
nonspecif
screen
mani
differ
virus
sometim
use
identifi
certain
virus
vivo
adventiti
viru
test
conduct
inocul
anim
sever
speci
supernat
cell
bank
materi
speci
chosen
optim
detect
possibl
contamin
adventiti
virus
vivo
viru
test
capabl
detect
array
virus
complimentari
detect
vitro
assay
list
virus
detect
given
tabl
ii
type
adventiti
viru
test
accept
specif
detect
viru
addit
nonspecif
test
varieti
specif
test
mani
differ
virus
may
requir
current
cell
fine
use
support
adenoviru
replic
human
origin
varieti
human
viru
test
includ
fdaapprov
test
kit
use
avail
although
cell
line
use
produc
adenoviru
gener
thought
support
replic
sever
virus
experiment
data
preclud
possibl
exist
addit
sensit
cellfinespecif
ident
test
part
mcb
character
possibl
human
cell
line
could
present
may
serv
reservoir
field
virolog
chap
virus
addit
surpris
virus
thought
rephcat
cell
line
hek
human
embryon
kidney
fibroblast
detect
adenoviru
product
lot
reason
test
current
recommend
variou
step
adenoviru
vector
product
current
specif
viru
test
includ
epsteinbarr
viru
ebv
hepat
b
viru
hbv
hepat
c
viru
hcv
cytomegaloviru
cmv
human
immunodefici
virus
ii
hiv
human
parvoviru
human
tlymphotroph
virus
htlv
adenoassoci
viru
aav
test
method
specif
sensit
test
submit
part
propos
accept
criteria
cell
bank
nonhuman
cell
line
could
also
use
produc
adenoviru
vector
case
addit
test
may
necessari
exampl
rodent
cell
use
mcb
also
test
appropri
antibodi
product
test
murin
antibodi
product
map
rat
antibodi
product
rap
hamster
antibodi
product
flap
current
adenoviru
product
method
commonli
use
fetal
bovin
serum
fb
porcin
trypsin
propag
produc
cell
line
use
fb
carri
two
type
risk
potenti
patient
exposur
bse
adventiti
bovin
virus
use
porcin
trypsin
carri
risk
patient
exposur
porcin
parvoviru
produc
cell
line
suffici
document
may
usabl
without
test
bovin
porcin
virus
bse
fb
use
suffici
document
includ
follow
certif
analysi
coa
show
fb
one
countri
usda
list
countri
bse
found
fb
test
bovin
virus
porcin
trypsin
suffici
document
includ
coa
show
trypsin
neg
porcin
parvoviru
document
viral
test
unavail
test
request
per
cfr
mcb
test
shown
accept
histori
nonexposur
agent
test
may
omit
subsequ
stage
product
coa
fb
porcin
trypsin
contain
proper
test
come
approv
geograph
locat
although
tumorigen
test
often
request
acknowledg
cell
line
use
adenoviru
product
may
tumorigen
immunodefici
mous
strain
later
stage
product
develop
test
may
requir
product
phase
clinic
test
may
possibl
omit
test
suffici
test
product
cell
substrat
dna
see
addit
safeti
test
character
mcb
includ
test
ident
cell
line
isoenzym
analysi
show
cell
line
correct
speci
current
adenoviru
produc
cell
involv
test
human
isoenzym
morpholog
also
assess
show
cell
line
retain
expect
shape
size
develop
cellspecif
ident
test
current
recommend
accident
contamin
adenoviru
vector
produc
cell
line
detect
work
cell
bank
expand
cell
popul
deriv
mcb
test
defin
number
cell
gener
test
wcb
similar
request
mcb
consist
follovs
safeti
test
steril
mycoplasma
vitro
adventiti
viru
character
includ
morpholog
isoenzym
analysi
master
viru
bank
mvb
consist
wellcharacter
stock
virusbas
vector
serv
inoculum
subsequ
largescal
vector
product
sometim
refer
vector
seed
stock
tabl
iii
give
summari
type
character
recommend
fda
safeti
test
master
viru
bank
similar
done
master
cell
bank
thu
master
viru
bank
test
steril
mycoplasma
vitro
vivo
adventiti
viru
specif
virus
ebv
hbv
hcv
cmv
hiv
aav
htlv
cell
use
produc
mvb
fulli
character
describ
mcb
depend
degre
character
fb
porcin
trypsin
mvb
may
requir
test
bovin
virus
porcin
parvoviru
addit
test
cell
bank
adenoviru
mvb
test
replicationcompet
adenoviru
rca
rca
common
byproduct
adenoviru
vector
product
current
consid
safeti
risk
rca
often
aris
due
molecular
recombin
vector
endogen
element
produc
cell
line
genom
recombin
restor
replic
compet
normal
replicationdefect
vector
give
rise
rca
exampl
hek
celllin
endogen
el
sequenc
requir
allov
replic
el
defect
adenoviru
vector
vector
undergo
homolog
recombin
endogen
el
thu
restor
replic
compet
stochast
unavoid
consequ
biolog
certain
produc
cell
develop
produc
cell
smaller
region
homolog
vector
endogen
sequenc
may
reduc
homolog
recombin
may
still
support
nonhomolog
recombin
replic
defect
adenoviru
vector
rca
test
perform
inocul
test
materi
onto
cell
line
support
replic
rca
defect
vector
supernat
treatment
passag
second
cell
monolay
develop
cytopath
effect
cpe
lysi
indic
presenc
rca
current
recommend
specif
rca
rca
total
x
viru
particl
character
adenoviru
vector
mvb
encompass
varieti
approach
establish
physic
biochem
biolog
properti
vector
prepar
ident
import
paramet
demonstr
intend
product
actual
start
materi
largescal
product
current
fda
recommend
structur
character
adenoviru
vector
includ
determin
nucleotid
sequenc
transgen
insert
flank
region
remaind
structur
demonstr
techniqu
restrict
map
pcr
case
extens
character
transgen
protein
avail
sequenc
necessari
restrict
map
vector
would
suffici
howev
recent
meet
brmac
address
issu
structur
character
recommend
vector
kb
length
character
sequenc
entir
vector
genom
like
fda
adopt
recommend
near
futur
adenoviru
vector
mvb
would
appropri
materi
sequenc
analysi
anoth
import
characterist
adenoviru
vector
mvb
activ
transgen
although
potenc
assay
per
se
paramet
suggest
therapeut
transgen
function
clinic
trial
therebi
justifi
risk
exposur
patient
activ
assay
includ
demonstr
transgeneencod
protein
express
demonstr
protein
function
biochem
assay
assay
determin
express
activ
adenoviru
vector
part
accept
criteria
mvb
method
accept
specif
assay
part
ind
submiss
number
adenoviru
vector
particl
mvb
measur
two
way
one
method
determin
particl
count
often
determin
measur
amount
dna
vector
prepar
relat
particl
number
agreedupon
convers
factor
although
physicalchem
assay
precis
affect
sever
factor
includ
formul
vector
prepar
nonvir
nucleic
acid
content
prepar
cellular
nucleic
acid
well
differ
dna
sequenc
vector
affect
precis
measur
vari
order
second
measur
adenoviru
vector
quantiti
mvb
infecti
titer
assess
mani
particl
retain
capac
interact
cell
surfac
receptor
subsequ
undergo
intern
measur
indic
manufactur
process
gentl
enough
preserv
viral
coat
protein
structur
larg
determin
abil
adenoviru
prepar
infect
patient
cell
therebi
introduc
desir
genet
materi
assay
subject
much
variabl
particl
number
determin
recent
year
sourc
variabl
identifi
concentr
diffus
rate
adenoviru
particl
two
import
paramet
consid
infecti
titer
assay
util
adher
cell
sit
bottom
tissu
cultur
dish
sinc
adenoviru
particl
settl
solut
instead
randomli
diffus
volum
materi
test
profound
impact
appar
infecti
titer
recent
initi
develop
adenoviru
refer
materi
lead
increas
accuraci
particl
infecti
particl
determin
refer
materi
consist
wildtyp
adenoviru
known
particl
infecti
titer
produc
distribut
comparison
differ
adenoviru
vector
prepar
within
lot
made
use
refer
materi
index
calibr
assay
done
differ
place
differ
time
test
final
adenoviru
vector
product
consist
safeti
test
product
character
test
involv
physicalchem
biolog
assess
tabl
iv
provid
summari
current
recommend
test
wherea
product
intermedi
mcb
mvb
subject
accept
criteria
final
product
character
subject
lot
releas
record
coa
specifi
test
method
sensit
result
safeti
test
similar
done
necess
specif
character
assess
casebycas
basi
chang
depend
phase
product
develop
result
feedback
numer
sourc
discuss
therefor
list
intend
give
reader
overview
fda
oversight
howev
consult
cber
strongli
recommend
submiss
ind
test
done
unpurifi
bulk
order
maxim
sensit
deplet
final
product
mcb
mvb
thu
steril
mycoplasma
test
perform
test
endotoxin
level
final
formul
product
lal
per
cfr
pyrogen
test
cfr
b
adventiti
viru
test
consist
vitro
viru
test
test
aav
rca
gener
vivo
adventiti
viru
test
recommend
final
product
adventiti
viru
test
perform
unpurifi
bulk
order
maxim
sensit
deplet
final
product
one
test
requir
licens
product
gener
safeti
cfr
current
recommend
rca
rca
per
x
viru
particl
current
recommend
final
product
character
similar
mvb
howev
ident
structur
character
need
done
dna
sequenc
analysi
rather
method
sensit
restrict
map
combin
southern
blot
analysi
pcr
map
may
use
show
final
vector
prepar
homogen
within
limit
assay
activ
assay
use
mvb
use
final
vector
prepar
develop
potenc
assay
reflect
intend
biolog
function
vector
prepar
commenc
soon
possibl
product
develop
place
end
phase
begin
phase
test
method
sensit
specif
lot
releas
submit
part
ind
submiss
number
particl
infecti
titer
per
unit
volum
measur
report
current
recommend
ratio
total
particl
infecti
particl
final
product
greater
previou
recommend
develop
shortli
first
adenoviru
vector
trial
vere
initi
remain
constant
recent
howev
review
data
receiv
respons
march
letter
genetherapi
sponsor
suggest
almost
adenoviru
vector
lot
ratio
less
particl
infecti
particl
advanc
understand
infecti
titer
assay
develop
adenoviru
refer
materi
help
reassess
recommend
near
futur
product
character
also
includ
assess
potenti
impur
product
cell
dna
protein
cell
line
use
product
tumorigen
current
fda
recommend
adenoviru
vector
product
ngdose
cell
substrat
dna
present
addit
dna
present
degrad
size
less
bp
length
criteria
met
need
tumorigen
assay
cell
substrat
less
press
current
recommend
cell
substrat
protein
sponsor
measur
report
amount
present
order
set
lot
releas
accept
criteria
phase
iii
cell
substrat
protein
present
potenti
immunogen
consid
potenti
impur
also
assess
analysi
final
product
includ
fetal
bovin
serum
tissu
cultur
reagent
antibiot
process
residu
cscl
column
chromatographi
materi
test
may
necessari
includ
ph
formul
final
product
assess
particul
volum
appear
necess
extent
test
discuss
fda
lotreleas
test
product
summar
certif
analysi
accompani
vector
product
final
consider
product
character
vector
stabil
stabil
test
conduct
final
formul
vial
product
earli
phase
product
develop
stabil
test
also
assess
procedur
ship
handl
final
product
stabil
test
initi
phase
conduct
accord
plan
discuss
fda
develop
new
adenovir
vector
gene
transfer
preclin
pharmacolog
toxicolog
program
typic
conduct
conjunct
develop
product
manufactur
overal
purpos
preclin
anim
vitro
studi
support
safeti
rational
use
product
human
subject
although
uniqu
gene
therapi
vector
gener
specif
adenovir
vector
develop
sever
basic
goal
achiev
preclin
test
vhich
contribut
design
conduct
initi
clinic
trial
includ
limit
identif
dose
confer
desir
biolog
effect
ii
definit
safe
start
dose
escal
scheme
iii
identif
pharmacodynam
measur
biolog
activ
iv
identif
safeti
toxic
paramet
monitor
clinic
trial
v
definit
inclus
andor
exclus
criteria
base
observ
toxic
final
vi
design
stop
rule
clinic
trial
base
toxic
profil
observ
anim
initi
pharmacolog
activ
propos
vector
system
evalu
either
vitro
vivo
demonstr
proof
concept
studi
design
determin
feasibl
effici
gene
transfer
whether
biolog
activ
correct
genet
defect
confer
desir
respons
observ
eg
multidrug
resist
hematopoiet
stem
cell
avail
anim
model
mimic
human
diseas
either
genet
pharmacolog
mechan
may
use
proof
principl
demonstr
transfer
gene
actual
abl
correct
genet
defect
amelior
slow
progress
diseas
allevi
clinic
sign
symptom
base
respons
observ
preclin
pharmacolog
program
decis
made
investig
either
evalu
candid
vector
safeti
intent
enter
clinic
termin
develop
potenti
unsuccess
product
preclin
pharmacolog
data
provid
cber
support
ind
applic
nih
rac
support
use
adenovir
vector
gene
transfer
sever
differ
clinic
indic
data
publicli
review
discuss
biolog
activ
adenovir
vector
evalu
murin
tumor
model
murineihuman
tumor
xenograft
transgen
mous
model
human
diseas
eg
ornithin
transcarbamylas
defici
human
cell
xenograft
immunodefici
rat
andor
mice
pharmacolog
induc
diseas
state
rodent
monkey
dog
advantag
use
adenovir
vector
abil
transduc
varieti
differ
nondivid
cell
type
high
level
gene
express
rel
short
durat
time
larg
enough
capac
carri
rel
larg
transgen
sequenc
next
step
precun
program
candid
gene
transfer
vector
toxicolog
test
prior
initi
entri
new
drug
biolog
agent
human
basi
determin
vivo
safeti
preclin
test
perform
anim
toxicolog
studi
demonstr
safeti
gene
transfer
vector
includ
adenoviru
intend
answer
specif
question
regard
accept
riskibenefit
ratio
patient
provid
indic
expect
toxic
may
occur
introduct
product
human
tradit
drug
develop
program
evalu
safeti
small
molecul
protein
therapeut
typic
conduct
toxicolog
test
normal
anim
use
welldefin
paradigm
establish
acut
subchron
cumul
toxic
agent
prior
first
use
man
least
two
anim
speci
use
initi
demonstr
safeti
typic
test
done
rodent
ie
mice
rat
hamster
one
nonrod
speci
ie
dog
pig
nonhuman
primat
advantag
approach
wide
rang
dose
may
investig
give
high
multipl
expect
human
exposur
metabol
disposit
profil
differ
speci
may
establish
basi
comparison
clinic
dose
background
incid
specif
advers
find
may
welldocu
particular
strain
anim
test
use
one
speci
tradit
drug
evalu
program
encourag
increas
chanc
detect
toxic
expect
clinic
trial
tradit
toxicolog
program
howev
frequent
littl
valu
determin
safeti
gene
transfer
agent
mani
vector
develop
issu
speciesspecif
transgen
product
studi
well
limit
dose
feasibl
administ
interact
agent
specif
receptor
must
taken
account
design
safeti
program
gene
transfer
research
demonstr
safeti
must
also
take
account
toxic
due
express
transgen
ultim
therapeut
agent
well
advers
effect
associ
vector
deliveri
system
use
introduc
foreign
gene
addit
underli
patholog
associ
diseas
investig
may
either
exacerb
confound
toxic
relat
gene
transfer
system
point
must
consid
design
preclin
program
evalu
safeti
efficaci
gene
transfer
agent
fda
recogn
novel
issu
exist
design
interpret
preclin
studi
gene
transfer
vector
provid
sever
guidanc
document
assist
investig
develop
preclin
program
cber
recent
publish
guidanc
document
provid
framework
design
preclin
safeti
program
gene
therapi
base
avail
data
vitro
vivo
efficaci
model
well
specif
concern
clinic
popul
plan
studi
cber
document
follow
guidanc
set
forth
intern
confer
harmon
document
preclin
safeti
evalu
biotechnologyderiv
pharmaceut
ich
although
ich
guidanc
directli
address
toxicolog
studi
design
gene
transfer
agent
mani
principl
document
appli
gener
toxic
studi
design
gene
transfer
agent
follow
mani
principl
set
forth
ich
regard
dose
speci
select
rout
administr
studi
time
point
address
separ
context
gene
transfer
understand
safeti
gene
transfer
vector
design
preclin
studi
take
consider
follow
point
class
vector
administ
ii
anim
speci
gender
age
physiolog
state
relev
clinic
indic
product
class
iii
intend
dose
rout
administr
treatment
regimen
plan
clinic
trial
mani
gene
transfer
vector
consider
depend
rout
administr
maxim
feasibl
dose
preclin
studi
may
influenc
speci
select
test
vice
versa
recent
death
patient
particip
clinic
trial
adenovirusmedi
gene
transfer
well
find
data
rhesu
monkey
use
class
vector
rout
administr
predict
mani
toxic
observ
subject
highlight
import
preclin
data
relev
anim
model
determin
safeti
profil
agent
cber
recommend
select
speci
safeti
evalu
adenovir
vector
gener
follow
guidanc
set
forth
ich
document
take
account
limit
anim
model
test
preclin
pharmacolog
safeti
test
vector
gene
transfer
employ
appropri
pharmacolog
relev
anim
model
avail
contrast
tradit
drug
develop
program
mani
biolog
product
includ
gene
transfer
vector
safeti
evalu
toxicolog
test
singl
relev
speci
permiss
prior
phase
studi
clinic
relev
anim
speci
would
one
biolog
respons
therapi
would
expect
mimic
human
respons
relev
anim
speci
safeti
evalu
may
also
select
base
clinic
popul
intend
studi
andor
intend
rout
administr
speciesspecif
transgen
product
case
interact
transgen
product
specif
receptor
occur
human
nonhuman
primat
necessit
toxicolog
test
monkey
mani
case
howev
toxic
observ
independ
transgen
product
eg
inflammatori
reaction
respons
adenoviru
capsid
protein
may
test
rodent
speci
small
nonrod
laboratori
speci
case
specif
inform
regard
safeti
gene
transfer
approach
may
obtain
anim
model
diseas
underli
diseas
patholog
influenc
significantli
safeti
intervent
evalu
pharmacolog
activ
vector
anim
model
clinic
indic
recommend
safeti
data
gather
time
order
assess
contribut
diseaserel
chang
physiolog
underli
patholog
respons
vector
gene
transfer
studi
human
anim
expect
involv
either
singl
administr
small
number
repeat
administr
short
durat
time
cber
recommend
rout
administr
dose
schedul
anim
studi
mimic
intend
clinic
trial
close
possibl
howev
issu
specif
gene
transfer
need
incorpor
studi
design
exampl
persist
gene
express
follow
transduct
target
organ
impact
upon
durat
toxic
studi
anoth
exampl
would
physic
characterist
agent
studi
ie
vector
aggreg
high
concentr
dose
rout
administr
preclin
safeti
studi
cellular
gene
therapi
mimic
intend
clinic
trial
close
possibl
understood
howev
dose
techniqu
andor
regimen
intend
clinic
trial
may
difficult
achiev
small
anim
speci
rodent
case
method
administr
similar
plan
use
clinic
advis
exampl
intrapulmonari
instil
adenovir
vector
intranas
administr
cotton
rat
mice
accept
approach
lieu
direct
intrapulmonari
administr
bronchoscop
current
recommend
dose
select
safeti
test
base
demonstr
efficaci
model
provid
gene
transfer
suffici
pharmacolog
effect
well
inclus
dose
likelihood
demonstr
toxic
dose
select
base
preliminari
activ
data
studi
vitro
vivo
determin
safeti
noobserv
advers
effect
level
dose
noael
overtli
toxic
dose
sever
intermedi
dose
evalu
determin
dose
relationship
toxic
amount
vector
administ
andor
transgen
express
also
evalu
shape
steep
doserespons
curv
preclin
safeti
studi
includ
one
dose
equival
least
one
dose
escal
level
exceed
propos
clinic
trial
multipl
human
dose
requir
determin
adequ
safeti
margin
may
vari
class
vector
employ
relev
anim
model
human
allometr
scale
dose
base
either
bodi
weight
total
bodi
surfac
area
appropri
facilit
comparison
across
speci
allov
determin
retrospect
vhether
anim
model
predict
toxic
observ
clinic
exampl
adenovir
vector
use
cystic
fibrosi
demonstr
similar
toxic
direct
instil
lung
cotton
rat
mice
hamster
rhesu
monkey
baboon
tabl
v
toxic
includ
doserel
perivascular
peribronchiolar
inflamm
mononuclear
inflammatori
cell
infiltr
pulmonari
edema
interstiti
pneumonia
noael
dose
calcul
speci
scale
total
bodi
surfac
area
except
rhesu
monkey
discov
valu
remark
similar
differ
speci
addit
scale
total
bodi
surfac
area
noael
dose
mice
cotton
rat
hamster
baboon
direct
instil
adenoviru
lung
approxim
equival
human
dose
x
lu
x
lum
first
dose
human
toxic
observ
scale
bodi
surfac
area
baboon
rhesu
monkey
human
treat
adenovir
vector
encod
cftr
via
bronchoscop
instil
isol
lobe
lung
anim
vere
sacrif
day
vector
administr
histolog
section
lung
examin
microscop
evid
inflamm
human
data
obtain
via
chest
radiogram
ct
scan
patient
phase
clinic
trial
noael
avail
lowest
dose
test
minimum
patholog
toxic
dose
human
x
lu
x
lum
find
allow
redesign
clinic
approach
gene
therapi
cystic
fibrosi
use
smaller
volum
instil
vector
target
approach
deliv
adenoviru
larger
airway
epitheli
surfac
date
cystic
fibrosi
patient
treat
use
two
three
log
higher
dose
adenoviru
newer
approach
without
toxic
observ
initi
clinic
trial
case
gene
transfer
vector
may
limit
suppli
vector
inher
low
toxic
maximum
feasibl
dose
may
administ
highest
level
test
preclin
studi
studi
especi
use
anim
model
clinic
indic
appropri
control
naiv
vehicletr
anim
includ
allow
determin
adequ
margin
safeti
use
vector
clinic
trial
well
accept
doseescal
scheme
one
issu
direct
administr
genet
modifi
cell
viral
vector
inject
materi
may
stay
initi
introduc
therefor
local
studi
design
determin
distribut
vector
traffick
genet
modifi
cell
administr
propos
site
incorpor
toxicolog
test
studi
two
purpos
first
identifi
potenti
distribut
vector
site
intend
target
site
presenc
vector
andor
aberr
express
transgen
may
lead
toxic
ii
evalu
potenti
distribut
vector
gonad
tissu
andor
transfect
germ
cell
discuss
nih
rac
risk
potenti
inadvert
gene
transfer
germ
cell
conclud
risk
vertic
transmiss
foreign
gene
small
discuss
rac
sever
expert
panelist
gene
transfer
reproduct
biolog
recommend
unless
signific
safeti
issu
associ
either
vector
transgen
product
preclin
biodistribut
studi
anim
alway
requir
prior
initi
phase
trial
addit
panel
conclud
case
adenovir
vector
larg
bodi
literatur
exist
regard
distribut
potenti
toxic
minor
chang
vector
eg
substitut
differ
transgen
potenti
toxic
associ
requir
preclin
distribut
studi
prior
initi
clinic
trial
biodistribut
studi
disposit
vector
detect
administr
intend
clinic
rout
provid
data
regard
potenti
gonad
uptak
inadvert
germlin
gene
transfer
also
identifi
target
organ
aberr
vector
distribut
gene
express
may
detriment
cber
current
recommend
biodistribut
studi
gene
transfer
agent
alway
requir
prior
phase
clinic
trial
howev
studi
incorpor
drug
develop
plan
data
avail
prior
commenc
largescal
pivot
studi
clinic
dose
level
select
biodistribut
studi
fouovvr
use
toxic
studi
includ
either
vehicl
untreat
control
anim
rout
administr
relev
employ
clinic
trial
transfer
gene
normal
surround
distal
tissu
vell
target
site
evalu
use
sensit
detect
method
possibl
includ
evalu
gene
persist
aberr
unexpect
local
observ
studi
conduct
determin
whether
gene
express
vhether
presenc
associ
advers
effect
addit
group
anim
may
treat
intraven
vorstcas
scenario
case
vhere
widespread
vector
dissemin
may
expect
caus
toxic
organ
target
site
preclin
studi
support
use
gene
transfer
vector
includ
adenoviru
clinic
studi
conduct
complianc
vith
regul
good
laboratori
practic
glp
set
forth
cfr
part
complianc
vith
regul
intend
assur
qualiti
integr
anim
safeti
data
use
support
human
research
studi
vell
market
approv
often
confus
type
studi
need
conduct
glp
regul
preclin
pharmacolog
proofofconcept
efficaci
studi
anim
well
vitro
pharmacolog
studi
expect
conduct
full
complianc
glp
howev
vitro
anim
toxicolog
studi
includ
singleand
repeatdos
toxic
test
reproduct
toxic
carcinogen
studi
gene
transfer
research
biodistribut
studi
expect
follow
guidelin
set
forth
regul
although
studi
gene
transfer
vector
earli
stage
clinic
develop
need
full
complianc
glp
regul
ie
qualiti
assur
audit
valid
test
methodolog
may
omit
earli
studi
cber
expect
pivot
toxicolog
studi
submit
ind
licens
applic
conduct
auspic
glp
goal
clinic
test
provid
inform
product
safeti
effect
ultim
allow
new
product
come
marketplac
discuss
introduct
precun
section
principl
describ
neither
uniqu
gene
transfer
vector
gener
adenovir
vector
particular
premarket
clinic
test
proce
stepwis
fashion
often
refer
phase
clinic
develop
although
phase
alway
discret
phase
studi
perform
market
phase
product
clinic
test
seri
goal
object
primari
goal
phase
test
learn
product
safeti
pharmacokinet
profil
identifi
safe
dose
dose
studi
phase
studi
involv
small
number
studi
particip
close
monitor
develop
drug
effect
common
phase
design
singl
dose
rise
dose
cohort
studi
escal
next
dose
cohort
occur
suffici
safeti
assess
proceed
cohort
start
dose
dose
escal
scheme
employ
depend
data
glean
product
preclin
test
clinic
data
avail
eg
close
relat
product
product
studi
differ
popul
dose
escal
usual
proce
defin
endpoint
maxim
toler
dose
optim
biolog
dose
reach
phase
studi
drug
may
conduct
healthi
volunt
approach
common
anticip
sideeffect
product
expect
minim
transient
target
popul
diseas
condit
interest
high
background
rate
advers
event
make
difficult
teas
safeti
profil
product
howev
mani
class
drug
biolog
includ
adenoviru
gene
transfer
product
potenti
shortand
longterm
advers
effect
see
section
xiii
gener
make
risk
unaccept
test
healthi
volunt
next
phase
clinic
test
phase
build
upon
inform
gener
prior
studi
goal
phase
test
gain
preliminari
evid
product
activ
diseas
condit
interest
begin
character
activ
phase
ideal
time
optim
dose
andor
dose
regimen
patient
popul
respons
paramet
like
reflect
clinic
benefit
well
build
upon
safeti
databas
phase
trial
often
random
control
conduct
multicent
phase
clinic
test
includ
clinic
studi
establish
product
effect
number
efficaci
trial
trial
design
size
safeti
databas
necessari
determin
net
clinic
benefit
depend
number
factor
includ
limit
class
product
develop
condit
diseas
studi
avail
therapi
phase
clinic
test
studi
conduct
market
approv
purpos
address
question
aros
premarket
investig
evalu
product
relat
sett
elderli
peopl
advanc
stage
diseas
design
postmarket
studi
random
control
clinic
trial
registri
depend
question
address
good
clinic
practic
gcp
set
principl
procedur
intend
preserv
protect
right
confidenti
human
research
subject
assur
extent
possibl
clinic
research
gener
valid
scientif
data
origin
code
conduct
protect
human
subject
clinic
research
date
back
nuremberg
war
trial
declar
helsinki
fda
auspic
intern
confer
harmon
ich
publish
guidanc
document
entitl
good
clinic
practic
gcp
consohd
guidelin
basic
principl
gcp
discuss
reader
refer
cber
websit
http
wwwfdagovcberguidelineshtm
full
document
sponsor
overse
ind
commun
fda
set
forth
regul
cfr
subpart
ich
gcp
guidelin
oversight
function
includ
select
studi
investig
report
safeti
inform
fda
provid
accur
time
inform
investig
case
sponsor
may
transfer
oblig
contract
research
organ
cro
although
sponsor
retain
ultim
respons
ind
clinic
investig
also
specif
oblig
delin
cfr
subpart
ich
gcp
guidelin
investig
respons
select
studi
particip
base
elig
requir
protocol
obtain
protocolspecifi
evalu
investig
respons
welfar
studi
subject
hisher
clinic
site
includ
collect
safeti
data
report
safeti
inform
ind
sponsor
investig
also
must
account
investig
medic
product
maintain
accur
record
provid
annual
updat
institut
review
board
irb
obtain
consent
studi
particip
sponsor
investig
distinct
separ
role
former
overse
latter
incorpor
check
balanc
minim
bia
maxim
patient
safeti
trial
valid
check
balanc
may
lack
investig
also
sponsor
addit
extern
oversight
advis
individu
physician
assum
role
sponsor
investig
sponsorinvestig
familiar
guidanc
feder
regul
set
respect
duti
sponsor
investig
advers
event
collect
report
fundament
aspect
drug
develop
human
subject
protect
clinic
investig
individu
identifi
evalu
document
advers
event
experienc
studi
particip
site
vho
respons
updat
ind
sponsor
irb
appropri
set
forth
feder
regul
cfr
sponsor
respons
submit
safeti
inform
fda
time
report
format
depend
natur
advers
event
sponsor
must
report
fda
write
seriou
unexpect
advers
event
inform
associ
use
investig
product
within
calendar
day
receipt
inform
unexpect
lifethreaten
fatal
event
associ
use
investig
product
must
report
telephon
facsimil
within
calendar
day
receipt
inform
per
cfr
telephon
written
report
constitut
expedit
report
although
causal
assess
integr
expedit
report
determin
given
investig
product
caus
associ
advers
event
cours
clinic
studi
alway
possibl
reliabl
way
assess
contribut
test
articl
advers
event
compar
advers
event
rate
sever
treatment
control
group
random
control
trial
howev
infrequ
earli
phase
clinic
test
although
one
alway
certain
relationship
administr
studi
product
advers
event
level
suspicion
requir
report
quit
low
except
reason
possibl
product
caus
contribut
unexpect
seriou
advers
event
event
must
report
fda
accord
specifi
time
frame
sponsor
also
requir
submit
ind
annual
report
includ
summari
frequent
seriou
advers
event
cfr
icfl
guidelin
entitl
structur
content
clinic
studi
report
describ
manner
safeti
data
individu
studi
organ
present
regulatori
author
market
applic
market
applic
includ
integr
summari
entir
safeti
experi
product
fda
part
ich
process
develop
guidelin
entitl
common
technic
document
registr
pharmaceut
human
use
address
among
item
format
integr
safeti
data
market
passiv
surveil
system
allow
continu
collect
report
safeti
inform
product
one
pose
uniqu
longterm
risk
activ
type
postmarket
followup
requir
gener
prospect
particip
enrol
trial
without
consent
element
consent
form
consent
process
set
forth
cfr
part
consent
studi
particip
must
inform
known
potenti
toxic
may
occur
particip
trial
investig
product
even
likelihood
toxic
remot
irb
institut
particip
studi
must
reviev
approv
consent
form
clinic
research
protocol
studi
initi
institut
composit
duti
irb
describ
ich
gcp
guidelin
cfr
part
disord
target
gene
therapi
inborn
error
metabol
affect
popul
vill
pediatr
subject
mechan
exist
strengthen
human
subject
protect
studi
particip
may
particularli
vulner
children
give
valid
consent
child
enrol
research
studi
parent
legal
guardian
consent
give
permiss
child
studi
fda
part
ich
process
publish
guidanc
document
address
clinic
trial
children
includ
ethic
issu
rare
circumst
vhere
possibl
obtain
particip
consent
natur
ill
injuri
obtain
consent
legal
accept
repres
eg
next
kin
feasibl
fda
may
permit
clinic
trial
proceed
waiver
consent
set
forth
cfr
monitor
audit
fundament
aspect
gcp
although
purpos
similar
assur
appropri
trial
conduct
data
valid
approach
differ
state
ich
gcp
document
monitor
act
overse
progress
cunic
trial
ensur
conduct
record
report
accord
protocol
standard
oper
procedur
gcp
applic
regulatori
requir
medic
monitor
usual
employe
sponsor
perform
onsit
indic
offsit
evalu
trialrel
activ
extent
frequenc
monitor
appropri
length
complex
particular
trial
among
function
monitor
identif
deviat
protocol
conduct
sponsor
may
take
appropri
correct
step
eg
retrain
investig
close
certain
site
etc
audit
defin
ich
cgp
document
systemat
independ
examin
trialrel
activ
document
audit
usual
conduct
conclus
trial
sponsor
may
hire
auditor
document
find
written
report
sponsor
fda
field
inspector
also
conduct
independ
studi
audit
tradit
purpos
fda
audit
verifi
data
submit
fda
support
market
applic
howev
fda
sponsor
may
conduct
caus
direct
audit
stage
clinic
investig
reason
suspect
problem
trial
conduct
data
integr
fda
perform
direct
inspect
gene
therapi
chnical
site
sinc
agenc
also
audit
approxim
gene
transfer
clinic
site
select
random
assess
whether
system
problem
conduct
clinic
studi
exist
inspect
find
discuss
detail
section
xvi
addit
measur
human
subject
protect
use
data
monitor
committe
dmc
evalu
accumul
data
clinic
trial
gener
sponsor
establish
dmc
includ
select
member
devis
charter
dmc
member
independ
sponsor
clinic
investig
role
dmc
vari
accord
charter
natur
studi
dmc
usual
empow
recommend
studi
modif
enhanc
safeti
particip
case
dmc
may
recommend
studi
stop
data
indic
major
safeti
concern
note
dmc
review
data
submit
visit
site
directli
ensur
data
accur
protocol
follow
consent
document
etc
thu
dmc
perform
function
obviat
need
studi
monitor
fda
process
develop
guidanc
dmc
complet
ongo
adenovir
vector
clinic
trial
earli
uncontrol
trial
absenc
intern
control
group
limit
abil
draw
definit
conclus
contribut
adenoviru
vector
product
advers
event
despit
caveat
regard
causal
assess
administr
replic
defect
adenoviru
associ
acut
cellular
cytokin
mediat
inflammatori
respons
individu
experienc
system
reaction
fever
chill
hypotens
laboratori
find
consist
dissemin
intravascular
coagul
includ
thrombocytopenia
overwhelm
system
inflammatori
respons
attribut
least
part
death
volunt
trial
ornithin
transcarbamylas
otc
defici
receiv
intrahepat
arteri
inject
high
dose
adenoviruscontain
product
observ
clinic
trial
includ
employ
system
administr
similar
dose
adenoviru
vector
see
also
discuss
section
xvi
rout
administr
appear
play
key
role
determin
type
occurr
advers
event
toxic
particularli
promin
organ
site
adenoviru
inject
includ
lung
brain
liver
addit
rout
administr
variabl
associ
chnical
trial
may
influenc
natur
frequenc
sever
advers
event
factor
includ
adenoviru
construct
transgen
dose
frequenc
product
administr
host
factor
underli
diseas
comorbid
use
concomit
medic
committe
expert
conven
discuss
adenoviru
safeti
decemb
question
role
transgen
toxic
profil
suggest
employ
null
adenoviru
vector
control
vhen
possibl
teas
rel
toxic
transgen
vector
preexist
antibodi
adenoviru
andor
develop
antibodi
respons
fouow
administr
adenoviruscontain
product
may
play
role
product
safeti
although
clear
relationship
establish
limit
data
avail
suggest
correl
high
baselin
level
neutral
antibodi
adenoviru
toxic
activ
moreov
studi
involv
repeat
administr
adenoviruscontain
product
particip
develop
larg
spike
serum
level
neutral
antibodi
initi
dose
howev
toxic
profil
first
subsequ
dose
similar
suggest
lack
correl
import
clinic
investig
continu
character
immun
statu
studi
particip
baselin
follow
adenoviru
vector
administr
attempt
correl
advers
event
level
chang
antibodi
titer
ultim
inform
could
util
patient
select
criteria
clinic
monitor
enhanc
safeti
effect
longterm
safeti
gene
transfer
activ
discuss
concern
late
advers
sequela
new
malign
occur
year
decad
follow
administr
replicationcompet
integr
virus
result
fda
guidanc
regard
test
replicationcompet
retroviru
rcr
product
patient
serum
lifelong
clinic
monitor
recommend
current
limit
retrovir
vector
ind
although
adenoviru
becom
replic
compet
fda
previous
recommend
patient
expos
class
product
follow
long
term
longterm
followup
gene
therapi
product
discuss
recent
meet
biolog
respons
modifi
advisori
committe
fda
revis
recommend
long
term
follow
recipi
gene
transfer
product
includ
adenoviruscontain
product
pend
addit
public
discuss
goal
phase
test
determin
adenoviru
contain
product
bioactiv
determin
whether
observ
activ
find
togeth
safeti
profil
warrant
clinic
test
bioactiv
measur
may
laboratori
find
clinic
outcom
combin
two
one
measur
bioactiv
gene
therapi
product
detect
gene
transfer
gene
express
may
possibl
assay
transgen
yet
develop
insensit
low
level
express
document
clinic
surrog
outcom
andor
altern
assess
eg
pharmacodynam
measur
correl
level
gene
express
highli
desir
earli
product
develop
extent
gener
data
feasibl
depend
among
factor
natur
product
clinic
popul
studi
state
scienc
regard
assay
detect
transgen
major
clinic
investig
adenovir
vector
date
target
patient
cancer
oncolog
set
studi
phase
develop
usual
design
captur
data
tumor
respons
complet
partial
respons
rate
demonstr
adenoviru
gene
therapi
product
result
certain
level
tumor
respons
character
respons
rate
complet
partial
respons
durat
respons
etc
along
accept
safeti
profil
usual
suffici
evid
activ
warrant
efficaci
trial
earli
studi
cystic
fibrosi
cf
involv
topic
administr
adenoviru
product
contain
cystic
fibrosi
transmembran
regul
cftr
protein
gene
nasal
epithelium
measur
product
activ
includ
gene
transfergen
express
assess
potenti
differ
across
nasal
epithelium
topic
administr
result
low
level
gene
transfer
limit
pharmacodynam
affect
gene
transfer
via
aerosol
deliveri
system
appear
margin
improv
topic
administr
given
limit
product
bioactiv
seen
clinic
develop
adenoviru
contain
product
cf
larg
abandon
evolv
area
clinic
research
use
adenovir
vector
product
contain
gene
intend
promot
vascular
growth
patient
enrol
gener
vascular
diseas
studi
ongo
cardiac
peripher
vascular
diseas
set
activ
measur
includ
laboratori
measur
myocardi
perfus
measur
gene
express
fda
grant
market
approv
product
shown
safe
effect
efficaci
standard
applic
fdaregul
product
state
section
food
drug
cosmet
act
substanti
evid
defin
evid
consist
adequ
wellcontrol
investig
includ
clinic
investig
expert
qualifi
scientif
train
experi
evalu
effect
drug
involv
basi
could
fairli
respons
conclud
expert
drug
effect
purport
repres
condit
use
prescrib
recommend
suggest
label
propos
label
thereof
follov
paragraph
address
issu
qualiti
quantiti
clinic
investig
provid
substanti
evid
adequ
well
control
investig
one
whose
design
execut
produc
valid
scientif
data
clinic
investig
intend
show
efficaci
must
control
effect
intervent
distinguish
influenc
spontan
chang
placebo
effect
bias
observ
phase
test
control
trial
help
teas
advers
event
assess
magnitud
effect
rel
control
group
inform
use
sampl
size
calcul
efficaci
trial
choic
control
eg
histor
activ
placebo
etc
depend
clinic
set
agenc
approv
product
market
base
studi
variou
type
control
group
type
control
advantag
limit
reader
refer
ich
guidanc
entitl
elo
choic
control
clinic
trial
extens
discuss
topic
control
adenoviralcontain
gene
transfer
product
could
adenoviru
vector
without
transgen
ie
contain
null
vector
discuss
previous
null
vector
control
could
help
delin
safeti
efficaci
vector
separ
insert
well
show
vector
insert
contribut
product
effect
null
vector
control
deem
appropri
could
incorpor
earlier
product
develop
rather
phase
might
benefici
determin
earli
contribut
need
transgen
adenoviru
product
current
phase
test
patient
malign
design
addon
trial
ie
chemotherapi
product
vs
chemotherapi
placebo
addit
treatment
placebo
feasibl
trial
blind
would
case
control
arm
could
receiv
placebo
import
util
object
outcom
measur
control
use
concomit
therapi
measur
object
blind
third
parti
assessor
may
use
trial
intend
provid
substanti
evid
efficaci
must
adequ
addit
wellcontrol
must
conduct
accord
gcp
discuss
section
xii
maxim
human
subject
protect
data
valid
must
also
design
appropri
relev
endpoint
either
reflect
clinic
outcom
accept
surrog
endpoint
surrog
endpoint
laboratori
measur
directli
indic
clinic
benefit
expect
correl
predict
clinic
benefit
surrog
endpoint
usual
easier
measur
clinic
endpoint
occur
earlier
cours
diseas
allow
shorter
smaller
thu
less
expens
studi
major
disadvantag
uncertainti
surround
whether
extent
surrog
reflect
true
clinic
benefit
thu
fda
base
import
regulatori
decis
regard
product
licensur
surrog
medic
commun
base
practic
decis
data
gener
trial
use
surrog
critic
surrog
valid
particular
treatment
diseas
surrog
valid
one
treatment
diseas
use
particular
product
extent
valid
appli
product
class
across
product
class
could
becom
import
particularli
one
might
defin
product
class
context
adenoviralcontain
product
earlier
phase
clinic
test
use
surrog
endpoint
may
serv
use
potenti
less
problemat
role
instanc
product
develop
surrog
may
use
assess
doserespons
thu
provid
rational
dose
select
later
trial
may
use
initi
proofofconcept
base
decis
clinic
develop
sever
excel
paper
provid
indepth
discuss
surrog
valid
surrog
diseas
seriou
life
threaten
without
accept
altern
treatment
may
possibl
establish
efficaci
receiv
fda
approv
base
trial
employ
surrog
endpoint
yet
valid
reason
like
predict
clinic
benefit
product
market
base
effect
surrog
endpoint
phase
studi
requir
verifi
clinic
benefit
provis
set
forth
cfr
subpart
e
oncolog
aid
two
area
provis
use
frequenc
number
adequ
wellcontrol
trial
necessari
make
determin
substanti
evid
effect
discuss
fda
guidanc
sponsor
meet
agenc
end
phase
discuss
reach
agreement
critic
product
develop
issu
number
type
clinic
trial
size
safeti
databas
consid
necessari
file
market
applic
midseptemb
particip
clinic
studi
adenovir
vector
product
ornithin
transcarbamylas
otc
defici
becam
profoundli
compromis
ultim
die
day
receiv
experiment
product
intrahepat
arteri
infus
event
first
death
chnical
gene
transfer
trial
clearli
directli
attribut
administr
vector
result
number
regulatori
action
well
commit
fda
increas
sponsor
outreach
program
address
issu
relat
safeti
gene
transfer
vector
includ
adenoviru
effort
includ
safeti
symposia
held
conjunct
offic
biotechnolog
activ
oba
nation
institut
health
nih
ii
fda
issuanc
letter
march
gene
therapi
sponsor
request
provid
inform
regard
oversight
program
includ
manufactur
anim
data
ongo
futur
clinic
trial
iii
target
inspect
clinic
site
complianc
gene
transfer
protocol
conduct
site
iv
increas
sponsor
educ
train
issu
specif
gene
transfer
well
conduct
clinic
trial
gener
follow
death
studi
particip
discuss
otc
trial
immedi
place
clinic
hold
fda
initi
search
databas
identifi
protocol
involv
adenovir
vector
use
therapeut
intent
total
protocol
identifi
use
adenoviru
administ
either
system
intrahepat
arteri
infus
direct
inject
liver
sponsor
protocol
inform
death
patient
otc
trial
ask
provid
assess
safeti
toxic
adenoviru
clinic
studi
includ
maxim
dose
vector
administ
date
review
inform
provid
sponsor
one
clinic
trial
use
adenoviru
encod
tumor
suppressor
gene
administ
rout
inject
higher
dose
otc
vector
place
clinic
hold
pend
receipt
review
safeti
data
specif
trial
nih
oba
issu
call
investig
submit
safeti
inform
adenovir
vector
clinic
preclin
studi
decemb
oba
held
open
public
symposium
whose
purpos
examin
avail
scientif
technic
clinic
data
regard
adenovir
vector
gene
transfer
identifi
specif
safeti
issu
uniqu
adenoviru
make
recommend
gene
transfer
commun
addit
clinic
preclin
data
requir
investig
industri
academ
set
present
inform
regard
biolog
pathophysiolog
toxic
associ
adenoviru
infect
natur
rout
infect
well
differ
approach
use
gene
transfer
research
studi
preclin
studi
result
data
human
subject
adenovirusvector
trial
cystic
fibrosi
oncolog
metabol
disord
discuss
major
clinic
data
come
studi
oncolog
set
gener
comparison
data
across
differ
set
reveal
toxic
associ
adenoviru
whether
anim
human
subject
similar
consist
mainli
local
doserel
doselimit
inflammatori
respons
immun
cell
activ
find
consist
whether
viru
administ
bronchoscop
instil
lung
direct
inject
local
tumor
system
administr
patient
treat
adenoviru
vector
high
dose
found
exhibit
sign
clinic
toxic
similar
observ
patient
univers
pennsylvania
howev
incid
death
attribut
vector
even
studi
dose
higher
use
otc
trial
administ
intrahepat
arteri
infus
base
result
present
discuss
symposium
work
group
adenoviru
safeti
toxic
adsat
conven
oba
compos
clinician
scientist
fda
industri
academia
recommend
group
present
close
safeti
symposium
includ
need
addit
inform
regard
adenoviru
vector
standard
biodistribut
human
subject
well
preclin
studi
construct
databas
would
includ
preclin
data
could
predict
expect
toxic
clinic
well
data
human
subject
would
allow
comparison
safeti
across
number
differ
set
find
recommend
adsat
rac
recent
pubhsh
oba
fda
also
cosponsor
three
addit
safeti
symposia
clinic
trial
gene
transfer
sinc
decemb
meet
includ
discuss
safeti
issu
involv
develop
helperdepend
adenovir
vector
clinic
program
gene
transfer
cardiovascular
diseas
well
recent
discuss
potenti
tumorigen
adenoassoci
viral
vector
mous
model
human
glucuronidas
defici
week
follow
death
patient
otc
studi
fda
conduct
direct
inspect
clinic
site
institut
review
board
univers
pennsylvania
well
inspect
anim
experi
conduct
support
clinic
program
three
inspect
found
deviat
defici
includ
inadequ
clinic
monitor
oversight
clinic
trial
inadequ
report
advers
event
failur
follow
clinic
preclin
studi
protocol
result
direct
inspect
fda
place
remaind
clinic
studi
sponsorship
clinic
hold
issu
warn
letter
sponsor
clinic
investig
involv
otc
trial
director
preclin
laboratori
facil
fda
also
issu
notic
initi
disqualif
proceed
opportun
explain
nidpo
letter
princip
investig
redact
version
letter
avail
cber
websit
second
clinic
inspect
differ
site
use
differ
class
vector
gene
transfer
cardiac
peripher
vascular
diseas
also
found
numer
discrep
conduct
clinic
trial
complianc
regul
govern
investig
new
agent
result
two
inspect
fda
determin
systemat
review
procedur
ensur
complianc
regul
warrant
accomplish
two
specif
activ
march
fda
issu
letter
gene
therapi
ind
master
file
sponsor
request
inform
gene
transfer
product
character
review
preclin
safeti
studi
ensur
find
met
criteria
requir
expedit
report
per
cfr
submit
summari
procedur
ensur
adequ
monitor
adequ
oversight
copi
march
letter
avail
http
wwwfdagovcbergenetherapygtpubshtm
march
letter
sent
approxim
sponsor
hold
slightli
less
total
activ
ind
master
file
item
letter
question
regard
product
test
character
data
test
method
specif
inform
regard
product
produc
facil
qualiti
control
procedur
goal
ensur
gene
therapi
product
current
clinic
trial
adequ
test
contemporari
standard
ii
determin
test
requir
need
made
stringent
relax
iii
gather
inform
aid
develop
addit
guidanc
iv
gain
inform
concern
product
character
manufactur
process
arrang
order
move
product
forward
toward
licensur
v
develop
mechan
ensur
ind
annual
report
routin
contain
updat
inform
gener
sponsor
adenoviru
gene
transfer
trial
complianc
fda
recommend
expect
regard
adenoviru
vector
product
character
addit
review
adenoviru
vector
lot
inform
led
recent
chang
recommend
regard
vector
infecti
particl
total
particl
measur
vell
chang
recommend
regard
rca
addit
request
inform
manufactur
practic
march
letter
also
ask
sponsor
provid
summari
monitor
program
clinic
studi
conduct
ind
document
oversight
function
intent
confirm
bring
sponsor
complianc
vith
gcp
requir
cfr
subpart
describ
ich
gcp
guidanc
fda
review
descript
clinic
monitor
program
found
monitor
program
gener
incorpor
mani
activ
procedur
accord
vith
ich
gcp
guidanc
requir
list
cfr
subpart
howev
area
defici
note
includ
limit
lack
procedur
correct
remov
noncompli
investig
ensur
report
protocol
modif
fda
ensur
safeti
report
file
ind
time
fashion
last
question
march
letter
intend
remind
sponsor
certain
find
anim
experi
ie
sever
toxic
andor
death
studi
also
rise
level
expedit
report
ask
sponsor
verifi
data
relev
either
alreadi
submit
requir
regul
previous
submit
data
promptli
submit
ind
master
file
gener
sponsor
indic
alreadi
complianc
report
requir
data
site
inspect
chosen
random
specif
question
regard
background
inform
product
clinic
studi
develop
inspect
team
focus
conduct
protocol
report
advers
event
blind
studi
medic
applic
whether
clinic
end
point
met
cber
field
inspector
conduct
inspect
april
august
gener
inspect
found
sponsor
commerci
academ
well
clinic
investig
complianc
regul
site
inspect
current
activ
clinic
trial
never
initi
propos
studi
requir
action
fda
approxim
half
site
objection
condit
practic
identifi
inspect
team
howev
case
total
site
voluntari
action
correct
defici
call
three
site
identifi
offici
regulatori
action
ie
warn
letter
requir
common
defici
case
failur
follow
protocol
ii
inadequ
consent
form
iii
lack
support
data
case
report
form
entri
andor
discrep
sourc
document
case
report
form
iv
inadequ
drug
account
record
v
failur
notifi
institut
review
board
protocol
chang
advers
event
death
summari
target
inspect
gene
transfer
research
clinic
trial
demonstr
except
studi
conduct
accord
appropri
regul
guidanc
deviat
note
appear
similar
found
routin
inspect
phase
studi
tradit
biolog
agent
fda
continu
conduct
inspect
clinic
preclin
andor
manufactur
site
involv
gene
transfer
research
caus
well
routin
base
part
role
protect
safeti
patient
enrol
trial
cber
routin
involv
educ
train
activ
aim
sponsor
investig
involv
gene
transfer
research
howev
follow
death
patient
otc
defici
studi
agenc
recogn
need
inform
potenti
sponsor
issu
specif
conduct
gene
transfer
studi
also
issu
involv
design
clinic
program
element
gcp
educ
session
taken
place
variou
venu
includ
drug
inform
associ
dia
annual
meet
special
satellit
broadcast
cosponsor
dia
fda
annual
meet
societi
toxicolog
american
colleg
toxicolog
intern
societi
genet
anticanc
agent
meet
pharmaceut
research
manufactur
associ
meet
rac
annual
american
societi
gene
therapi
asgt
meet
fda
continu
particip
train
cours
held
asgt
well
profession
scientif
societi
adenoviru
vector
complex
biolog
fda
recommend
expect
product
manufactur
character
preclin
clinic
test
incorpor
tremend
experi
gain
nearli
year
sinc
first
adenoviru
gene
transfer
experi
well
experi
entir
field
gene
transfer
research
fda
cogniz
need
flexibl
recommend
consid
mani
factor
includ
intend
target
popul
serious
diseas
studi
potenti
benefit
risk
investig
product
advis
sponsor
adenoviru
develop
program
agenc
updat
reassess
recommend
adenoviru
vector
product
test
base
grow
experi
feedback
varieti
sourc
inform
section
intend
educ
reader
fda
process
expect
util
conjunct
consult
fda
staff
